Six disciplines. One team, end to end.

Confirm the target indication and its regulatory precedent before the program commits time and capital. We map precedent and in-review products to ground the pathway in real regulatory history, position the asset against current standard of care to define where the unmet need is clearest, and frame the intended label so development generates the evidence it will need.

Select the approval route that best fits the asset, its market, and the timeline. We weigh standard approval against accelerated options such as Orphan Drug Designation and provisional or accelerated pathways, then choose the combination that balances speed, evidence burden, and commercial protection.

Define the nonclinical evidence the chosen pathway will demand before studies begin. We scope ICH-aligned toxicology, set the PK/PD work needed to support dosing, and flag where GLP-standard studies are triggered, so the package holds up under regulatory review.

Map the phase sequence and endpoints regulators will expect to see. We plan how the phases connect, select endpoints that satisfy both regulators and payers, and identify where adaptive designs can save time without weakening the evidence.

Set the CMC and quality foundations early, before scale-up pressure forces rushed decisions. We establish GMP readiness, define product specifications, and build a stability strategy so the quality system supports the filing rather than holding it up.

Choose and characterise the lead candidate from the series before the program commits to a molecule. We rank candidates on developability, potency, and liability profile so the asset that enters the tox and CMC work is the one most likely to survive it.

Characterise how the candidate is absorbed, distributed, and cleared, and how exposure relates to effect. We build the PK/PD picture that guides dose selection and scheduling and that later clinical dosing decisions will rest on.

Run the ICH-aligned safety studies needed to clear the path to first-in-human. We cover multi-species single-dose and repeat-dose toxicity and genotoxicity, sized to the intended clinical route and duration so the safety package holds up under review.

Demonstrate the biological effect in models regulators and reviewers will find credible. We select the right in vitro and in vivo systems and design studies so the efficacy signal translates toward the clinic rather than stalling at the bench.

Establish a reproducible route to the drug substance and understand what comes with it. We develop the synthesis, profile process- and degradation-related impurities, and set the batch consistency needed before material carries regulatory weight.

Build the analytical foundation the filing will stand on. We develop the methods, set pharmacopeia and release specifications, and define the CMC package so quality is defined and defensible from the outset.

Prove the analytical methods are accurate, precise, and specific before they carry regulatory weight. We validate the assays that release material and underpin every downstream quality claim.

Run trials in children with the added rigour they require. We design age-appropriate protocols and dosing, build consent and assent processes that work for families, and put the safety monitoring in place that regulators expect for paediatric populations, so the study protects young participants and still delivers usable data.

Design the study that answers the question regulators and payers will actually ask. We define endpoints, set eligibility criteria, and build the statistical plan so the trial can support the claim it is meant to prove.

Prepare and manage ethics review so approvals arrive on time rather than blocking startup. We assemble the ethics dossier and informed consent materials and steer them through to approval.

Select sites that can actually recruit and deliver clean data. We assess recruitment potential, site capability, and realistic startup timelines before commitments are made.

Build the electronic data capture system the trial runs on, configured to the protocol rather than forced into a template. We design and validate the eCRFs, edit checks, and audit trails to 21 CFR Part 11 standards, so data is captured clean and stays inspection-ready from first entry.

Keep the trial compliant and the data clean from first patient to last. We handle source verification, protocol compliance, and safety oversight throughout the study.

Turn trial activity into a defensible, submission-ready dataset. We manage data capture and cleaning, map to CDISC SDTM and derive ADaM analysis datasets, then run the biostatistics behind the final conclusions, so the package is ready for regulatory review, not just internal reporting.

Set the regulatory route across the markets that matter before submissions begin. We align strategy across the TGA, FDA, and EMA so the program is built once for multiple agencies rather than reworked for each.

Engage regulators early to de-risk the program before major spend. We prepare pre-IND and scientific advice meetings and the briefing books that make those conversations count.

Prepare the applications that open clinical trials in each jurisdiction. We compile and manage INDs, CTAs, and CTNs so trials can start without avoidable delay.

Pursue the designations that accelerate review and add commercial protection. We assess and prepare Orphan Drug, Fast Track, and Breakthrough submissions where the asset qualifies.

Compile submissions to standard and manage the agency dialogue through to decision. We build the eCTD, manage publishing, handle agency responses, and run the meetings that keep the review moving.

Move the process from bench toward commercial-relevant scale without losing quality. We work through process design, scale factors, and yield so the route holds up as volumes grow.

Transfer the process to the manufacturing site cleanly and reproducibly. We handle documentation, operator training, and comparability so the receiving site makes the same product.

Prove the process reliably produces quality product batch after batch. We cover process, cleaning, and equipment validation to the standard regulators expect.

Qualify the suppliers and CMOs the supply chain depends on. We run audits, put quality agreements in place, and maintain the oversight that keeps GMP intact.

Finalise packaging and the testing that releases each batch to market. We address primary packaging, stability, and release testing for the regulated markets in scope.

Plan the market entry sequence and the access approach that makes launch land. We work through market sequencing, access, and pricing so approval turns into uptake.

Build the route that gets the product to customers across target markets. We set up channels, distributors, and logistics suited to each market's realities.

Shape the identity the product carries into a competitive market. We define positioning, visual identity, and messaging that hold up against the standard of care.

Design packaging that is compliant and still sells. We balance regulatory compliance, design, and labelling so the pack works on shelf and on file.

Sustain performance after launch with the support the product needs to keep going. We cover lifecycle management, pharmacovigilance, and reordering so momentum continues.